September 18th 2024
Your daily dose of the clinical news you may have missed.
September 17th 2024
New data shows that favorable CV health in the first trimester is associated with a 35% to 62% lower risk of HDP regardless of level of genetic risk.
September 13th 2024
Unawareness was highest among the youngest adults, aged 18 to 44 years, an age range where CV health should be optimized to avoid later morbidity, researchers wrote.
Approximately 10.5 million US adults, or 5% of the population, have the atrial fibrillation, according to new prevalence estimates.
September 12th 2024
Daily Dose: Pegozafermin in Patients with NASH
Your daily dose of clinical news you may have missed.
Loneliness Linked to Greater Risk for CVD in Individuals with Diabetes
The predictive value of loneliness for cardiovascular disease in patients with diabetes was stronger than traditional lifestyle risk factors in large UK Biobank analysis.
Pegozafermin Shows Early Promise in NASH: Phase 2b ENLIVEN Trial Findings
Pegozafermin, an investigational long-acting (FGF21) analogue, was associated with fibrosis improvement and NASH resolution in an average of 25% of study participants.
E-Cigarettes: US Sales Nearly Double over 2 Years, Youth Prefer Flavored Disposables
Sales of e-cigarettes in the US jumped by 46% from 2020-2022; rapid market shifts beg coordinated restrictions to protect public health, says the CDC.
Daily Dose: HF, CV Benefit of SGLT-2 Inhibition Consistent in T2D, CDK, HF
Studies of Novel, Highly Effective Antiobesity Medications Headline 83rd ADA Scientific Sessions
Retatrutide, survodutide, orforglipron. The 3 new GLP-1 agonist-based AOMs showed weight loss of up to 20% and are well worth watching.
Daily Dose: Bempedoic Acid Reduces Risk for MACE in Primary Prevention Population
Bempedoic Acid Reduced Risk for MACE by 30% in Primary Prevention Population: CLEAR Outcomes Subanalysis
ADA 2023: The only nonstatin therapy to reduce risk for 4-point MACE in ASCVD may potentially find a role in primary prevention as well, though caution is advised.
SGLT-2 Inhibitor HF, CV Benefit Found Consistent Across Populations with T2D, CKD, HF
SGLT-2 inhibitors were found to consistently reduce risk of CV mortality and HF events in a meta-analysis including 90 000 high-risk patients with T2D, CKD, and/or HF.
Daily Dose: Healthy Lifestyle & Risk of CVD Among Postmenopausal Women With Normal BMI
Home Blood Pressure Monitoring among Older US Adults
Among adults aged 50 to 80 years with a BP-related condition, less than half say they regularly monitor BP at home; one-third are "not very concerned" about their BP.
Daily Dose: Cardiovascular Safety of Testosterone-Replacement Therapy in Men with Hypogonadism
Healthy Lifestyle Linked to Primary CVD Prevention in Postmenopausal Women with Normal BMI
Higher scores on a healthy lifestyle index were associated with significantly reduced risk of incident CVD among women aged 50-79 years with BMI between 18.5 and 25.0.
FDA Approves Low-Dose Colchicine as First Anti-inflammatory Therapy to Reduce Cardiovascular Events
Colchicine 0.5 mg is associated with reduction in a wide range of CV events in patients already on statin therapy, supporting the long-held "anti-inflammatory" hypothesis.
Testosterone Replacement Does Not Increase Risk for CV Events in Men with Hypogonadism, New Study Finds
ENDO 2023. In older men with hypogonadism and CVD, there was no difference in incident CVD between those taking testosterone and those taking placebo.
Daily Dose: Bempedoic Acid Found Comparable to Statins for Lowering LDL-C
Friday's 5 Quotes for Primary Care 6-19-2023
Ozempic impact on patients, clinicians; bempedoic acid comparable to statins; hypertension risk upped with oral estrogen HT; and 2 more quotes of note.
Bempedoic Acid Found Comparable to Statins for Lowering LDL-C, Reducing Major CV Event Risk
ENDO 2023: Treatment with bempedoic acid was found comparable to statin therapy in an analysis of the CLEAR Outcomes trial based on CTT Collaboration methodology.
Daily Dose: Postmenopausal Women Using Oral Estrogen Hormone Therapy More Likely to Develop HTN
Daily Dose: Finerenone Reduces CKD-associated CV Risk in Patients with T2D
Risk of Hypertension in Postmenopausal Women Higher with Oral Estrogen-only Hormone Therapy
Oral estrogen hormone therapy was more likely to result in incident hypertension than transdermal or vaginal formulations in this large prospective population-based study.
Finerenone Reduces CKD-associated Composite Cardiovascular Risk in a New Subanalysis of FIDELITY Trial
Finerenone was associated with a decrease in composite CV risk in patients with CKD, T2D, eGFR of ≥25, and moderately to severely increased albuminuria.
Elevated Lp(a) Levels Found Independent Predictors of Recurrent CHD in Australian Cohort
Increased levels of lipoprotein(a) significantly and independently predicted recurrent CHD events in adults aged 60 years and older, report study authors.
Friday's 5 Quotes for Primary Care 6-9-2023
FDA fast tracks triple-threat antithrombotic, dangers of faux semaglutide online, a guide to neurologic sequelae of COVID-19, plus 2 more reviews of note.
Milvexian, FXIa Inhibitor, Wins US FDA Fast Track Designation for 3 Indications in Phase 3 Trial Program
Proposed indications for the investigational factor XIa inhibitor are: stroke prevention after acute ischemic stroke or high-risk transient ischemic attack; recent acute coronary syndrome; and atrial fibrillation.
Daily Dose: Adherence to GLP1RA, SGLT2i Therapies & Prescription Copayment Level
Lower Adherence with GLP1RA, SGLT2i Therapies Linked to Higher Prescription Copayments
In a new study of adults with T2D and/or HF, those with higher prescription copayments were less likely to achieve 1-year adherence to GLP1-RA and SGLT2i therapies.
The Long COVID Neuro Differential Dx: Sometimes Tricky, Always Nuanced
Coauthor of a new multidisciplinary guidance statement on assessment of neurologic sequelae of long COVID highlights a consensus on steps to rule the condition out.
Friday's 5 Quotes for Primary Care 6-2-2023
The world's first RSV vaccine and the virus surveillance that is missing, PCPs missing opportunities to treat obesity, T2D linked to subclinical CVD, and more news.
Diabetes Associated with Higher Risk of Death in Persons Hospitalized with Acute Myocardial Infarction
After an acute myocardial infarction, adults with diabetes were over 50% more likely to die after 1 year than those without diabetes, a new study shows.